ABSTRACT
A novel coronavirus infection was described in 2019 in Wuhan, China. From the first months of the spread of the infection around the world, evidence began to appear that patients after recovery had various symptoms. Duration, intensity, and variability of symptoms vary among patients and are often not associated with the severity of the most acute illness. Recently the concept of post-COVID syndrome (postCOVID or long-COVID in the English-language literature) has acquired increasingly clear diagnostic criteria. Persistent symptoms and / or the appearance of delayed complications after 4 weeks or more from the onset of symptoms of an acute illness are commonly called post-COVID syndrome. The wide range of symptoms that can occur in patients with post-COVID syndrome is now a major health concern worldwide. A proper clinical evaluation will help determine the etiology and build a treatment plan. Longer studies aimed at identifying the effects of COVID-19, possible risk factors for their development, a detailed study of the pathogenetic mechanisms of SARS-CoV-2, and the development of treatment and rehabilitation methods to improve the mental and physical health of surviving patients are relevant elements of study for the foreseeable future. T-lymphocytes are a poorly studied population of T lymphocytes. These cells are more often localized in the mucous membranes of the body which have the properties of innate and acquired immunity. The main biological functions are cytolysis, immunoregulation which indicates an important immunocompetent role of this type of cell population in severe infectious diseases. This article provides information on the fraction of T-lymphocytes during the formation of adaptive immunity in patients with post-COVID syndrome.
ABSTRACT
Acute viral respiratory infections add to the progression risk of the already existing pathologies, including those of cardiovascular origin. Life-threatening complications emerging against SARS-CoV-2 (severe acute respiratory syndrome), which causes COVID-19 (Coronavirus disease 2019), explain the need to study the cardiovascular effects of COVID-19 in order to offer rational medical care to patients belonging to various age categories. This article presents a comprehensive assessment of changes affecting the main hemostasis parameters in patients with acute cerebral circulatory disorders against the SARS-CoV-2 virus infection. There is special attention paid to the pathophysiological features occurring against the infectious process involving the hemostasis system. Our data shows that the differences in the main hemostatic parameters in patients with acute cerebral circulatory disorders occurring against the SARS-CoV-2 virus infection are due to the degree of the body responsiveness and the severity of the comorbid pathology. Reducing the risk of adverse conditions developing in this category of patients is possible in case of responsible monitoring focusing on the main indicators of the cardiovascular system status, as well as provided there are advanced approaches introduced in order to prevent and treat thrombotic/thromboembolic complications.